Metlife Stock Earnings Reports

MetLife reported a strong Q1 2026, demonstrating broad-based revenue and earnings growth and continued progress on its New Frontier strategy. Adjusted earnings were $1.6 billion ($2.42 per share), up 18% year-over-year (adjusted EPS +23%), and adjusted ROE was 17% (top of the 15%–17% target). Variable investment income (VII) was $518 million pretax, driven by strong private equity and venture returns. Operating highlights included resilient margins, improved expense efficiency (direct expense ratio 11.9%, beating the 12.1% 2026 target), and growth across key segments: Group Benefits (adjusted earnings $439M, +19%), Retirement & Income Solutions (RIS $451M, +11%), Asia ($487M, +31% with strong Japan and Korea sales), Latin America ($229M, +5%), EMEA ($110M, +33%), and the first fully integrated quarter of MetLife Investment Management (MIM) including PineBridge (MIM adjusted earnings $47M, +68%). Capital management was active and disciplined: ~ $1.1B returned to shareholders in Q1 (including ~$750M buybacks), a 4.4% dividend increase, a $1B subordinated debt issuance (oversubscribed), and holding-company liquidity of $3.9B (top of $3–4B target). Management reiterated confidence in the strategy and outlook, noting the quarter strengthens conviction in delivering on multi-year targets. Key risks/notes: some net investment/trading losses due to portfolio rotations and opportunistic secondary PE sales (~$750M sold at a modest discount), modest early post-close outflows at MIM but a strong pipeline, regulatory review activity in Japan (company says practice discontinued and working with regulators), and normal seasonality impacts in Group Benefits (dental/disability) expected to moderate into H2. Overall message: durable, diversified earnings, disciplined capital allocation, and continued investment in tech/AI to drive growth and efficiency.